About HALO study

  • To identify how these conditions and their treatment might impact on individuals’ long-term health and quality of life.
  • To identify unmet needs and health inequalities.
  • To use this information to direct where improvements in care and support are needed.

We have co-produced a participant information video with our Patient and Public, Involvement and Engagement (PPIE) group introducing the HALO study HALO video link.

Anyone diagnosed with

  1. Acute leukaemias (lymphoblastic and myeloid) or,
  2. A sickle cell disorder or,
  3. Beta thalassaemia currently or previously requiring red cell transfusion.

The are 2 parts to the study: data linkage and survey.

In the data linkage part of the study, we will access routinely collected information on the above groups of people using NHS England sources, national registries, educational and social care data sources. These will be used to conduct data linkage and provide important information on patients’ journeys across multiple aspects of life.

We will invite people who are at least 18 years old and are registered with or under the care of specialist haematology teams in the North of England or cancer services at Leeds Teaching Hospitals NHS Trust and Sheffield Teaching Hospital NHS Foundation Trust to take part in a survey about their condition and treatment.